PNA Clamp Kits
PNAClamp Technology is the PNA-based PCR clamping that selectively amplifies only the mutated target DNA sequence as a minor portion in the mixture with the major wild type DNA sequences. It takes full advantages of the nature of PNA probes that has strong binding affinity and specificity to its target DNA and not being recognized by DNA polymerase as primer.
PNAClamp Mutation detection kits can use DNA samples from surgical tissue or formalin-fixed paraffin-embedded biopsies (FFPE).
PNAClamp Mutation detection kits offer many advantages over conventional methods.
We also provide dedicated technical support to set up and to analyze data.
EGFR Mutation Details
The epidermal growth factor receptor (EGFR) is a family member of Receptor tyrosine kinases, expressed on the surface of epidermal cells. Overexpression or overactivation of EGFR is linked to a number of cancers, including lung cancer, anal cancers and glioblastoma multiform.
The PNAClamp EGFR Mutation Detection Kit detects most prevalent mutations described to date in the EGFR gene, including T790M, the presence of which correlates with resistance to tyrosine kinase inhibitors. Detecting somatic mutations in EGFR gene may provide a useful strategy to predict the response to the tyrosine kinase inhibitors in efforts to increase the survival rate of lung cancer patients receiving targeted therapy.
< Mutations detected by PNAClamp EGFR Kit>
| Exon | Amino acid change | Base change |
| 18 | Gly719Ala | 2156 G>C |
| Gly719Ser | 2155 G>A | |
| Gly719Cys | 2155 G>T | |
| 19 | Glu746_Ala750del | 2235_2249 del 15 |
| Glu746_Thr751delinslle | 2235_2252 AAT (complex) | |
| Glu746_Ser752del | 2236_2253 del 18 | |
| Glu746_Thr751delinsAla | 2237_2251 del 15 | |
| E746_S752>A | 2237_2254 del 18 | |
| Glu746_Ser752delinsVal | 2237_2255 >T (complex) | |
| Glu746_Ala750del | 2236_2250 del 15 | |
| Glu746_Ser752delinsAsp | 2238_2255 del 18 | |
| L747_A750>P | 2238_2248 >GC (complex) | |
| Leu747_Thr751delinsGln | 2238_2252 >GCA (complex) | |
| Leu747_Glu749del | 2239_2247 del 9 | |
| Leu747_Thr751del | 2239_2253 del 15 | |
| Leu747_Ser752del | 2239_2256 del 18 | |
| Leu747_Glu749del:Ala750Pro | 2239_2248 TTAAGAGAAG>C | |
| Leu747_Pro753delinsGln | 2239_2258 >CA (complex) | |
| Leu747_Thr751delinsSer | 2240_2251 del 12 | |
| Leu747_Pro753delinsSer | 2240_2257 del 18 | |
| Leu747_Thr751del | 2240_2254 del 15 | |
| Leu747_Thr751deinsPro | 2239_2251 >C (complex) | |
| 20 | Thr790Met | 2369 C>T |
| Ser768lle | 2303 G>T | |
| Ala767_Val769dupAlaSerVal | 2307_2308 ins9 | |
| His773dupHis | 2319_2320 insCAC | |
| Asp770_A771insGly | 2310_2311 insGGT | |
| 21 | leu858Arg | 2573 T>G |
| leu861Gln | 2582 T>A |
KRAS Mutation Details
KRAS mutation is found in several cancers including colorectal, lung, thyroid, and pancreatic cancers and cholangiocarcinoma. KRAS mutations are often located within codons 12 and 13 of exon 2, which may lead to abnormal growth signaling by the p21-ras protein. These alterations in cell growth and division may trigger cancer development as signaling is excessive.
A KRAS mutation often serves as a useful prognostic marker of drug response. For example, a KRAS mutation is considered to be a strong prognostic marker of response to tyrosine kinase inhibitors such as gefitinib (Iressa) or erlotinib (Tarceva). Recently, KRAS mutations have been detected in many colorectal cancer patients and may be associated with responses to cetuximab (Erbitux) or panitumumab (Vectibix), which are used in colon cancer therapy.
< Mutations detected by PNAClamp KRAS Kit>
| Codon | Mutation | Base change |
| Codon12 | Gly12Asp | 35G>A |
| Gly12Ala | 35G>C | |
| Gly12Val | 35G>T | |
| Gly12Ser | 34G>A | |
| Gly12Arg | 34G>C | |
| Gly12Cys | 34G>T | |
| Codon13 | Gly13Ser | 34G>T |
| Gly13Arg | 37G>C | |
| Gly13Cys | 37G>T | |
| Gly13Asp | 38G>A | |
| Gly13Ala | 38G>C | |
| Gly13Val | 38G>T | |
| Codon59 | Ala59Ser | 175G>T |
| Ala59Thr | 175GA | |
| Ala59Glu | 176C>A | |
| Ala59Gly | 176C>G | |
| Ala59del | 176_178 del CAG | |
| Codon61 | Gly60Asp | 179G>A |
| Gly60Ala | 179G>C | |
| Gly60Val | 179G>T | |
| Gly60Gly | 180T>A | |
| Gly60Gly | 180T>C | |
| Gln61Glu | 181C>G | |
| Gln61Lys | 181C>A | |
| Gln61Leu | 182A>T | |
| Gln61Arg | 182A>G | |
| Gln61Pro | 182A>C | |
| Gln61His | 183A>T | |
| Gln61His | 183A>C | |
| Codon 117 | Lys117Glu | 349A>G |
| Lys117Arg | 350A>G | |
| Lys117Asn | 351A>C | |
| Lys117Asn | 351A>T | |
| Codon 146 | Ala146Pro | 436G>C |
| Ala146Thr | 436G>A | |
| Ala146Gly | 437C>G | |
| Ala146Val | 437C>T | |
| Ala146Ala | 438A>G | |
| Ala146Ala | 438A>C | |
| Ala146Ala | 438A>T |
NRAS Mutation Details
NRAS mutation is found in several cancers such as melanoma (13~25%), colorectal cancer(1~6%), lung cancer (1%), thyroid cancer (7%) and hepatocellular carcinoma (10%). It is knowthat the drug response against colorectal cancer medicine such as Erbitux and Cetuximabdecreased and the prognosis of the metastatic colorectal cancer patient is bad if the patient hasNRAS mutation.
| NRAS Mutation Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| · PNAC-1101 (43 mutations) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
BRAF mutation detection kit
B-raf mutation is found in several cancers including thyroid cancer, malignant melanoma, ovarian cancer, colorectal cancer.
ln case of thyroid cancer, there are over 40 different types of B-raf mutation. Of these mutations, V600E mutation on exon 15 (change from T to A in 1799th base) is most important with over 90% of frequency. Especially, B-raf V600E mutation is detected at about 45% of frequency in papillary thyroid carcinoma and is considered a prognostic maker for thyroid cancer.
ln addition, the B-raf mutation in colorectal cancer is reported as a prognostic marker for reduced drug response to cetuximad(Erbitux) or panitumuab (Vectibix). These results imply that the B-raf mutation detection is needed for diagnosis and prognosis for drug response in colorectal and thyroid cancers.
PI3K3CA Mutation Details
PI3K (Phosphoinositide 3-kinases or PI 3-Kinases) are family of lipid kinases capable of phosphorylating the 3' position hydroxyl group of the inositol ring of phosphatidylinositol. They are involved in coordinating a diverse range of cell functions including cell growth, proliferation, differentiation, motility, survival and intracellular trafficking.
Activating mutations in PI3K catalytic domain of the p110alpha subunit (PIK3CA) have recently been discovered in certain types of cancer cells. PIK3CA mutations are found at 25~40 % frequency in various types of tumors including colorectal cancer, gastric cancer, lung cancer, brain cancer, endometrial cancer, ovarian cancer, breast cancer. About 80% of the point mutations presides in exon 9 (a presumed helical domain) and exon 20 (a presumed kinase domain), while other types of mutations are also seen in different locations.
< Mutations detected by PNAClamp PIK3CA Kit>
| Tube No | Reagent | Amino Acid Change | Base change | Exon | Translation region |
| 1 | E542 | Glu542Lys | 1624 G>A | Exon 9 | Helical |
| Glu542Gly | 1624 A>G | ||||
| Glu542Val | 1624 A>T | ||||
| 2 | E545 | Glu545Lys | 1633 G>A | ||
| Glu545Gly | 1634 A>G | ||||
| Glu545Asp | 1635 G>T | ||||
| 3 | H1047 | His1047Tyr | 3139 C>T | Exon 20 | Kinase |
| His1047Leu | 3140 A>T | ||||
| His1047Arg | 3140 A>G |
IDH1 mutation detection kit
Mutations of IDH1 (isocitrate dehydrogenase 1, IDH1) can be found in glioblastoma and myeloproliferative neoplasm.
Detection of IDH1 mutations can be a positive predictor of a prognosis and a molecular marker for glioblasttoma patients. On the other hand, it is reported that IDH1 mutations correlate with poor prognosis in myeloproliferative neoplasm.
PNAClamp IDH1 Mutation Detection Kit detects a mutation in R132 position with high sensitivity.
- Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications. Bumrungthai S et al (2015) J Transl Med. 13:244.
- Impact of the Specific Mutation in KRAS Codon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three Trials. Modest DP et al. (2012)Oncology 83(5): 241-247.
- Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated withcetuximab. De Roock W et al. (2010) JAMA 304(16): 1812-1820.
- Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. Tejpar S et al. (2012) J Clin Oncol. 30(29): 3570-3577.
- Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation. Moyazawa H et al. (2008) Cancer Sci. 99(3): 595-600.
- Dissect Method Using PNA-LNA Clamp Improves Detection of EGFR T790M Mutation. Minakshi G et al. (2013) PLoS ONE. 8(6): e67782.
- Detection of EGFR Mutations in Archived Cytologic Specimens of Non-Small Cell Lung Cancer Using High-Resolution Melting Analysis. Nomoto K et al. (2006) Am J Clin Pathol. 126:608-615.
- High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection informalin fixed paraffin embedded biopsies. Do H et al (2008) BMC Cancer. 8(142):1-14.
Currently we are working on BCR-ABL (T315I, 944C>T) and JAK2 (V617F, 1849 G>T mutation)PNAClamp TM kits. We can also collaborate on custom genotyping development usingPNAClamp TM technology.
Please feel free to inquire about any other kits that are not listed Contact us
For quotation or order, please send us an email to
We usually respond within 6 hours after the inquiry was received. Also feel free to call at 805) 504-2220.
| Catalog No | Product Name | Description | Size | Price |
| PNAC-1002 | PNAClamp KRAS Kit (v2) | G12, G13 | 30 tests | |
| PNAC-1003 | PNAClamp KRAS Kit (v3) | G12, G13, Q61 | 25 tests | |
| PNAC-1004 | PNAClamp KRAS Kit (plus) | A59, K117, A146 | 25 tests | |
| PNAC-1006 | PNAClamp KRAS Kit (v4) | G12, G13, A59, Q61, K117, A146 | 25 tests | |
| PNAC-1101 | PNAClamp NRAS Kit (v4) | G12, G13, A59, Q61, K117, A146 | 25 tests | |
| PNAC-2001 | PNAClamp BRAF Kit | BRAF V600 mutation | 50 tests | |
| PNAC-3002 | PNAClamp EGFR Kit | G619, E19 del, T790, S768, E20 in, L858, L861 | 25 tests | |
| PNAC-4002 | PNAClamp PIK3CA Kit | E542, E545, H1047 | 25 tests | |
| PNAC-5001 | PNAClamp IDH1 Kit | R132 mutation | 25 tests |